Applied Therapeutics’ lack of progress on govorestat as well as the potential costs to come have led analysts to question ...

Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & ...

European life sciences investor Medicxi has raised 500 million euros (about $581.6 million) to go directly toward innovative ...

After already halving its workforce twice since 2022, Sensei Therapeutics is forging ahead with another deep round of cuts. | After already halving its workforce twice since 2022, Sensei Therapeutics ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. | Neuro biotech Ovid Therapeutics' C-suite is metamorphosing, with co ...

Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.

As part of that relocation, about 70 employees—less than 5% of the total at the site—are being laid off, the spokesperson said. Some affected staffers may be able to move to other positions within the ...

After dropping so-so early-stage results on its dual GLP-1/GLP-2 agonist earlier this year, fierce competition in the obesity ...

AbbVie is ending an eleven-year agreement with Alphabet’s Calico Labs, according to an internal email obtained by Stat News.

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. | Third ...

After forming from a merger hashed out over plates of tacos about a year ago, nChroma Bio is laying off staff and ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...